Alto Neuroscience, Inc. (ANRO)
Healthcare
Biotechnology
27.10 $
-5.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Alto Neuroscience, Inc. (ANRO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -27 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.6 | -7.8 | -12 | -11 | -12 | -12 | -13 | -17 | -14 | -9.9 | -12 | -27 | -62 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.7 | |
| 1.3 | 0.5 | 0.6 | 2.2 | 1.9 | 2.0 | 1.6 | 2.0 | 2.0 | 2.2 | 1.9 | 2.8 | 9.0 | |
| 0.6 | 0.8 | -1.2 | -0.3 | 1.4 | 2.8 | 0.1 | -4.7 | 1.3 | 1.3 | 2.1 | -4.4 | 0.3 | |
| 0.1 | 0.0 | 0.4 | 0.2 | 0.3 | 1.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.6 | |
| -0.1 | 0.0 | -0.4 | -0.2 | -0.3 | -1.0 | -0.5 | 0.0 | – | – | – | -0.6 | – | |
| – | -0.1 | – | – | – | 0.1 | – | 0.0 | 0.0 | – | -0.2 | -4.9 | – | |
| – | – | – | – | – | 0.0 | – | 9.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.1 | 0.0 | 43 | 135 | -0.2 | 1.3 | 0.0 | 9.1 | 0.6 | 0.2 | 50 | 115 | 166 | |
| -6.8 | -7.7 | 31 | 123 | -12 | -11 | -13 | -7.5 | -13 | -9.8 | 39 | 87 | 103 | |
| -6.7 | -7.8 | -12 | -11 | -12 | -13 | -14 | -17 | -14 | -9.9 | -12 | -28 | -63 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.